Tenacia Biopharmaceuticals and Golden Age Health Partner to Commercialize ZTALMY® for CDKL5 Deficiency Disorder in Mainland China
First-ever approved treatment for CDD in China now set for commercial launch through dedicated rare disease platform
SHANGHAI–(BUSINESS WIRE)–Tenacia Biopharmaceuticals (Shanghai) Co., Ltd. (“Tenacia“) and GOLDEN AGE HEALTH (SHANGHAI) CO., LTD., a subsidiary of Golden Age Health Pte. Ltd. (collectively, “GAH“) today announced a Commercialization Agreement granting GAH exclusive rights to commercialize ZTALMY® (泽元安), the first and as of now only approved treatment for CDKL5 deficiency disorder (CDD) in Mainland China.
ZTALMY® (ganaxolone oral suspension) was developed by Marinus and Tenacia obtains exclusive rights to develop and commercialize it in Greater China. In July 2024, the drug was approved by the National Medical Products Administration for treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.
Tenacia has partnered with GAH to leverage its comprehensive patient-focused commercialization platform—encompassing disease awareness, diagnosis support, market access, and patient affordability programs—to ensure this therapy reaches the families affected by this devastating rare epilepsy.
“Bringing the first approved therapy for CDKL5 deficiency disorder to patients in China represents exactly the type of mission-critical work Golden Age Health was built for,” said Chao (Brook) Wu, Chief Executive Officer of Golden Age Health (Shanghai). “We are honored to partner with Tenacia to ensure that children and families affected by CDD can access this breakthrough treatment as quickly as possible.”
Dr. Xiaoxiang Chen, Founder and CEO of Tenacia Biopharmaceuticals (Shanghai), said: “GAH’s proven expertise in rare disease commercialization and their commitment to patient access make them the ideal partner to bring ZTALMY® to the patients who need it most in China. Together, we will work to maximize the impact of this important therapy.”
About CDKL5 Deficiency Disorder
CDKL5 deficiency disorder (CDD) is a rare developmental epileptic encephalopathy caused by mutations in the CDKL5 gene. Patients typically experience early-onset, treatment-resistant seizures, profound developmental delays, and motor impairments. CDD is included in China’s National Rare Disease Catalog, reflecting the urgent need for effective treatments for affected patients and their families.
About ZTALMY® (ganaxolone oral suspension)
ZTALMY® (ganaxolone oral suspension) is a neuroactive steroid GABAA receptor positive allosteric modulator. The oral suspension formulation (110ml: 5.5g) is approved by China’s NMPA for the treatment of seizures associated with CDKL5 deficiency disorder in patients 2 years of age and older. It represents the first therapy specially approved for this indication in China.
About Golden Age Health
Golden Age Health is a specialty pharmaceutical company dedicated to redefining patient access to medicine across China, Asia-Pacific and MEA. Headquartered in Singapore, GAH pairs data-driven market-access expertise with deep medical-affairs and RWE capabilities to bring high-impact therapies to underserved populations.
About Tenacia Biopharmaceuticals
Founded in 2022 by Bain Capital, Tenacia is a commercial-stage biopharmaceutical company dedicated to developing innovative therapeutics for patients with underserved neurological disorders. Tenacia’s seasoned management team brings decades of drug development experience from both MNCs and biotechs. Their deep understanding of complex disease biology and insights into unmet patient needs enable Tenacia to create a highly efficient neuroscience R&D platform with a proven track record of advancing novel therapies. Empowered by its founder and strategic investor, Bain Capital – through significant initial investment, long-term commitment and extensive life science network – Tenacia is poised to become a leading neuroscience company in China and deliver substantial value to shareholders while upholding an unwavering commitment to the patients.
Forward-Looking Statements
This release contains forward-looking statements, including expectations regarding clinical development, regulatory matters and commercial launches. These statements involve risks and uncertainties that may cause actual outcomes to differ materially.
Contacts
Media & Investor Contacts
Golden Age Health
https://www.gahbioventures.com/
Media/IR: info@gahbioventures.com
Tenacia Biopharmaceuticals
官网：https://www.tenacia.com
You May Also Like
Flora Growth Announces $401M Funding to Boost AI Zero Gravity (0G) Coin Treasury
Highlights: Flora Growth announces $401M PIPE financing round aimed at establishing an AI Zero Gravity (0G) coin treasury. DeFi Development Corp. led the fundraising exercise with strong support from other companies. Flora Growth will rebrand to ZeroStack following the successful completion of the PIPE financing round. One of the world’s leading decentralised artificial intelligence (AI) treasury companies, Flora Growth, has announced the pricing of a $401 million private investment in public equity (PIPE) round. According to a September 19 press release, the move aims to fund the firm’s treasury strategy centred on AI Zero Gravity (0G) tokens. Upon completion of the PIPE round, Flora Growth will rebrand to ZeroStack, while still maintaining its current market ticker symbol, FLGC. Notably, the financing round is expected to close on or before September 26, 2025, pending customary approvals. Flora Growth Corp. (NASDAQ: FLGC) announced a $401 million PIPE financing led by Defi Development Corp., Hexstone Capital, and CSAPL. 0G Co-Founder Michael Heinrich will become Executive Chairman. The deal is expected to close on September 26. The company will adopt $0G as its… — Wu Blockchain (@WuBlockchain) September 19, 2025 Flora Growth Announces $401M PIPE with Strong Backing from Leading Crypto Firms DeFi Development Corp. (DFDV), the first treasury firm focused on Solana (SOL), led the financing round with a $22.88 million investment. Other partners included Hexstone Capital, Dispersion Capital, Blockchain Builders Fund, Carlsberg SE Asia PTE Ltd (CSAPL), Abstract Ventures, Salt, and Dao5. The fundraising exercise has already generated $35 million in cash commitments and $366 million worth of in-kind digital assets. Flora Growth sold its common shares and pre-funded warrants to investors at $25.19 per share. The company also pegged 0G tokens contribution at $3 per coin, adding that investors paying either cash or 0G tokens will also receive pre-funded warrants, exercisable once shareholder approval is granted. A big NASDAQ company (Flora Growth) just announced they’re raising $401 million. ︎ They plan to buy and hold $0G tokens as part of their company’s savings/treasury. Flora’s deal values $0G at around $3 per token for their planned purchase. Right now $0G is trading below… pic.twitter.com/qhOa3uT5ii — Jimmywontgiveup(Ø,G) (@jimmywontgiveup) September 20, 2025 Flora Growth Plans to Hold SOL in Its Treasury Flora Growth noted that it plans to hold part of its treasury in SOL. Joseph Onorati, the CEO of DeFi Development Corp., spoke on the partnership.“We’re thrilled to partner with FLGC on this fundraiser and look forward to driving a deep collaboration between 0G and Solana,” the CEO stated. Daniel Reis-Faria, Flora Growth’s incoming Chief Executive Officer (CEO), also spoke on the company’s latest initiative. He explained that the move encompasses financial restructuring and support for adopting AI infrastructures. The CEO commented: “This treasury strategy offers institutional investors equity-based exposure, enabling transparent, verifiable, large-scale, cost-efficient, and privacy-first AI development.” A Brief 0G Token Overview, Highlighting Reasons for Flora Growth’s Interest 0G is gaining significant traction, which has made experts describe the token as a breakthrough in decentralised AI. 0G’s model trained a 107 billion AI parameter model, representing a 357x improvement over Google’s DiLoCo research, challenging the idea that huge centralised data centres are needed for such projects. The 0G network proved that a decentralised network is highly effective for cost-effective computations, with transparent and privacy-first solutions. Unlike other AI blockchains, 0G integrated its computation, storage, and training marketplace into one platform, attracting Web2 and Web3 developers. In related news, Crypto2Community reported that Brera Holdings, an Ireland-based company, completed a $300 million PIPE financing round for a Solana-focused treasury on September 19. The fundraising program was led by Pulsar Group, a blockchain advisory firm based in the UAE. It received strong backing from the Solana Foundation, RockawayX, and ARK Invest. Like Flora Growth, Brera Holdings also rebranded to Solmate. eToro Platform Best Crypto Exchange Over 90 top cryptos to trade Regulated by top-tier entities User-friendly trading app 30+ million users 9.9 Visit eToro eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment, and you should not expect to be protected if something goes wrong.
XRP koers en de 21-maanden EMA: herhaling van geschiedenis of breuk met het patroon?
